COVID-19 | Latest research news from CSV members

Remdesivir
by Dr. Matthias Gotte (University of Alberta)

This is how remdesivir blocks coronavirus RdRp. Competes well with ATP, get's incorporated, still allows three nucleotides to be added and causes delayed chain-termination. Read-through can decrease inhibition. 

 

- Calvin Gordon et al Part 1: Remdesivir is currently tested in trials for the treatment of Covid-19. It potently inhibits the RNA polymerase of MERS-CoV:  asbmb.altmetric.com/details/76689582/news

- Editors' Picks Highlight: Comment on this paper by Robert Kirchdoerfer: jbc.org/content/295/15/4780.short
 
- Author Profile: Congrats Calvin (CSV member): jbc.org/content/295/15/4773/suppl/DCAuthor_profile
 
- Calvin Gordon et al. Part 2: Remdesivir is a direct-acting antiviral that targets the RNA polymerase of SARS-CoV-2:  asbmb.altmetric.com/details/79704798/news

 

Update:

SEPTEMBER 24, 2020

Lab uncovers new mechanism of action against SARS-CoV-2 by antiviral drug remdesivir
by University of Alberta Faculty of Medicine & Dentistry

Full text

 

Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action

Full text

 


 

To better understand COVID-19 by comparing disease progression in children and older adults.
 

Researchers from Université de Montréal and CHU Sainte-Justine are attempting to obtain insights into the pathogenesis of COVID-19 by comparing innate and adaptive immune responses in children infected with SARS-CoV-2 and in older adults, in whom symptoms of the disease are much more serious.
by :
Dr Jean-Sébastien Joyal (Université de Montréal, CHU Sainte-Justine)
Philippe Jouvet (Université de Montréal, CHU Sainte-Justine)
Dr Srinivas Murthy (University of British Columbia)

 

- Mieux comprendre la COVID-19 en comparant sa progression chez les enfants et les aînés: nouvelles.umontreal.ca/article/2020/04/02/mieux-comprendre-la-covid-19-en-comparant-sa-progression-chez-les-enfants-et-les-aines/

 


 

Comprendre la réponse immunitaire déclenchée par le virus COVID-19.
by Dr Louis Flamand (Université Laval, CHU de Québec)

 

- 2,1 M$ pour combattre le coronavirus: nouvelles.ulaval.ca/recherche/21-m-pour-combattre-le-coronavirus-52ef3e642ec6dd81b62d56ba141a44ef

- COVID-19: cibler les problèmes respiratoires: lesoleil.com/ulaval-nouvelles/covid-19-cibler-les-problemes-respiratoires-3ab8e55ee47adb65da57c1b33fa3788d

 


 

How we participated in the isolation of SARS-CoV-2 from patients in Toronto and the research we are currently doing.
by :
Dr. Arinjay Banerjee and Dr. Karen Mossman of McMaster University

Dr. Samira Mubareka and Dr. Rob Kozak of Sunnybrook and University of Toronto

 

- A (now isolated) scientist who isolated the COVID-19 virus explains the fight for a vaccine (Toronto Star): thestar.com/podcasts/thismatters/2020/03/30/a-now-isolated-scientist-who-isolated-the-covid-19-virus-explains-the-fight-for-a-vaccine.html

- Dr. Karen Mossman discusses what isolating a virus means: tsn.ca/radio/toronto-1050/dr-karen-mossman-discusses-what-isolating-a-virus-means-1.1457064

 


 

Back to news list

The CSV is an organization incorporated under the not-for-profit corporation Act #967119-6.